Log in to your Inderes Free account to see all free content on this page.
Lytix Biopharma
Be the first to follow this company
Lytix Biopharma is a biotechnology company in the clinical stage that develops new cancer immunotherapies. The company's technology is based on research in antimicrobial peptides, a defense aimed at pathogens. Lytix Biopharma's main product, LTX-315, is an oncolytic peptide for the purpose of personalizing immunotherapy. The company conducts its research and operations in Oslo.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
Euronext Growth Oslo
LYTIX
Daily low / high price
-
Market cap
-
Turnover
-
Volume
-
Financial calendar
Interim report
29.08.2024
Interim report
14.11.2024
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Citibank, N.A. | 9.2 % | 9.2 % |
Jakob Hatteland Holding AS | 7.5 % | 7.5 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Lytix Biopharma AS: Lytix Biopharma Q1 2024 results - Promising clinical progress with important upcoming milestones
Lytix Biopharma AS: Lytix Biopharma: Invitation to presentation of first quarter 2024 results, Thursday 30 May 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio